Wechsler memory scale-fourth edition (WMS-IV) in the neuropsychological evaluation of patients diagnosed with probable Alzheimer's disease.

There is a scarcity of research concerning Wechsler Memory Scale-Fourth Edition (WMS-IV) findings in Alzheimer's disease (AD). We provide information, beyond that in the test manual, concerning the power of the scale to detect AD-associated memory deficits. Participants were 87 individuals with diagnoses made according to criteria specified in the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5): 31 probable neurocognitive disorders due to AD and 33 patients with depression. Twenty-three elderly controls were also studied. The depressed and control participants had similar demographics as well as test scores and therefore were blended into a single control group (n = 56). AD patients were significantly impaired on the four WMS-IV indexes relative to controls, and the index pattern of performance differed across groups. Delayed Memory Index was a significant weakness in AD, whereas the Visual Memory Index was the lowest mean for controls. Sensitivity, specificity, hit rate, positive predictive value, and negative predictive value were strong to excellent for each index when a cutoff of 1.5 SDs below the normative mean was used to separate ADs and controls. Receiver operating characteristics curve analyses yielded excellent area under the curve statistics that ranged from .970 for the Visual Memory Index to .999 for the Delayed Memory Index. A supplementary analysis yielded similar results when the AD group was divided into mild (n = 10) and major (n = 21) subgroups.

Does high scatter on the Wechsler Adult Intelligence Scale-Fourth Edition general ability index reduce validity in predicting Wechsler Memory Scale-Fourth Edition indexes?

We examined whether significant scatter in WAIS-IV GAI will reduce its validity to predict performance on WMS-IV indexes. Participants were 330 individuals with neurological, psychiatric, or neurodevelopmental disorders and 59 referrals who were found to be free of a diagnosable disorder. For VCI > PRI, 59.32% were significant at p < .05 and 12.29% were >22 points. For VCI < PRI, 48.37% were significant at p < .05 and 7.19% were >22 points. Inter-subtest scatter across GAI subtests indicated 82.26% of individuals had a significant scatter range and 13.88% had an unusually large range (≥8). For the VCI, 49.10% had significant scatter (≥3) and 12.08% had an unusually large scatter range (≥5). On the PRI, 43.19% had a significant scatter range (≥4) and 12.85% had an unusually large degree of scatter (≥6). Moderation analyses revealed GAI was a significant predictor of each WMS-IV index. The interaction term of GAI with GAI scatter was not significant for any indexes, indicating that regression equations for predicting WMS-IV scores from GAI did not vary significantly across levels of scatter. Estimation of WMS-IV indexes from the GAI is justified even when significant VCI-PRI discrepancies are present and there is unusual variability across the GAI subtests.

Relative subtest scatter on the WAIS-IV in a clinical sample referred for outpatient neuropsychological evaluation.

OBJECTIVE: The primary aim of this study was to examine relative inter-subtest variability, or scatter, on the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) in a clinical sample of patients referred for neuropsychological evaluation and compare the findings to corresponding data from the scale's standardization sample. METHOD: Participants were 638 individuals diagnosed primarily with neurological, psychiatric, or neurodevelopmental disorders who completed the 10 core subtests of the WAIS-IV as part of a comprehensive assessment battery. RESULTS: Mean participant scores on the WAIS-IV Full Scale IQ and all index composites were within the average range, overall, but were significantly below those of the standardization sample. The correlation between scatter range and highest subtest scaled score was significant, r = .65, indicating a greater degree of subtest scaled score variability in participants with higher than average peak subtest scaled scores than participants with average or below peak subtest scaled scores. Mean variability by highest subtest scaled score was, in most cases, larger in this clinical sample relative to the scale's standardization sample. Exploratory secondary analyses also revealed specific differences in relative scatter based on diagnostic group classification. CONCLUSIONS: Subtest scatter on the WAIS-IV is common among both healthy individuals and clinical patients. Although somewhat higher in this investigation's clinical sample, the significance of this finding generally appears to be of nominal value during interpretation of individual cases but may have some utility in formulating hypotheses when considered in conjunction with reliability data and other approaches for analyzing test scores. High scatter is not pathognomonic of abnormality, and at least some degree of caution is warranted when interpreting subtest scaled score differences on the WAIS-IV.

Validity of the Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II) as an Indicator of Neurological Disease/Injury: A Pilot Study.

PURPOSE: Although the Wechsler Abbreviated Scale of Intelligence, Second Edition is commonly used by neuropsychologists in the assessment of intellectual functioning, there is a paucity of published literature examining its utility in detecting neurological disease/injury. This study constitutes an attempt to validate the four-subtest WASI-II (4-FSIQ) for use with patients with neurological disease/injury. METHOD: Participants were 59 patients referred for outpatient neuropsychological evaluation. Thirty-two individuals with diagnoses of dementia, stroke, traumatic brain injury, and other neurological disorders constituted the neurological group. A control group was comprised of 27 individuals with diagnoses of psychiatric disorders or age-related cognitive decline. RESULTS: The WASI-II subtest and composite scores of the neurological group were all significantly (ps < .0001) lower than those of the control sample, but pattern differences between the groups were absent. When premorbid IQs and WASI-II IQs were compared, neurological patients with neurological disease/injury displayed evidence of intellectual deterioration; whereas, control participants did not. CONCLUSIONS: Findings suggest that the 4-WASI-II is sensitive to the biological condition of the brain and provide preliminary validation for its use in the neuropsychological assessment of a diagnostically heterogeneous sample of patients with neurological disorders.

Psychometric evaluation of self- and collateral timeline follow-back reports of drug and alcohol use in a sample of drug-abusing and conduct-disordered adolescents and their parents.

One hundred eighty-eight drug-abusing and conduct-disordered adolescents and their parents provided retrospective reports of the youths' frequency of alcohol and illicit drug use for each of the 6 months preceding their initial session in an outpatient treatment program. Youths' and parent reports of youths' drug and alcohol use for each month were similar. For marijuana and alcohol, frequency reports were related for each month, whereas hard drug reports were related only for the 4 months preceding intake. Relationships among alcohol and hard drug reports were strong during Months 1, 2, and 4 preceding intake, whereas strength of relationship among marijuana reports was similar throughout the 6 months.

The Test of Memory Malingering (TOMM): normative data from cognitively intact, cognitively impaired, and elderly patients with dementia.

This research adds to the psychometric validation of the Test of Memory Malingering (TOMM) by providing data for samples of elderly patients who are cognitively intact, cognitively impaired (non-dementia), and with dementia. Subjects were 78 individuals referred for evaluation of memory complaints. Significant group differences emerged between the dementia group and the two other groups (normals and cognitively impaired), although the latter two did not differ from each other. One hundred percent of normals and 92.7% of the cognitively impaired group made fewer than five errors (the suggested cut-off) on Trial 2 or the Retention trial of the TOMM, yielding an overall correct classification rate of 94.7%. However, the rate of misclassification for persons with dementia was high whether using a cut-point score of five, eight, or ten errors. This investigation extends the validity and clinical utility of this instrument. Results suggest that the TOMM is an useful index for detecting the malingering of memory deficits, even in patients with cognitive impairment, but only when dementia can be ruled out.

Diagnostic challenges of using CSF assay of tau and beta-amyloid(42) in atypical degenerative dementias of the Alzheimer type.

This report presents three cases of atypical degenerative dementias in order to illustrate challenges associated with the use of biologic markers of Alzheimer's disease (AD) for diagnosis and management. Clinical diagnostic methods followed the NINCDS-ADRDA criteria for AD. Additional diagnostic studies included serial neurocognitive testing, MRI, neuroSPECT, ApoE genotyping, and a CSF assay of tau and beta-amyloid(42). For patient 1, both the clinical and biologic markers were consistent with AD. The patient was diagnosed with AD with a high degree of confidence, even though the base rate of nonfamilial AD at this age group (<55 years) is exceedingly rare. This case argues favorably for the use of biologic markers to aid in confirming a diagnosis in an atypical dementia. Patient 2 met the NINCDS-ADRDA criteria for AD, although with less confidence. Neurocognitive data indicated a progressive right hemispheric syndrome, insight was preserved, and ApoE was 3/3, but tau concentrations and beta-amyloid(42) were highly consistent with cut-offs for AD; the differential fell on the Pick's disease/frontotemporal degeneration spectrum. Patient 3 had no clinical evidence of the disease, even when evaluated via extensive neurocognitive testing over a 2-year interval. However, ApoE was 4/4, and CSF assay of tau and beta-amyloid(42) were within the AD range. Therefore, while the CSF assay of tau and beta-amyloid(42) markers was confirmatory of AD, each case was highly atypical. Results illustrate the lack of normative data available when using biologic markers for highly atypical cases, calling into question their usefulness for such patients. These cases illustrate the interplay between neuropsychological and biological markers in establishing neurodegenerative diagnoses.

Adolescents and their parents: a critical review of measures to assess their satisfaction with one another.

The importance of assessing the parent-adolescent relationship has been stressed in the literature. However, an integration of studies that have been conducted to assess satisfaction in the parent-adolescent relationship is warranted, including evaluation of measures to assess their satisfaction with one another. Therefore, the purpose of this paper is to provide a critical examination of the clinical utility and psychometric properties of such measures. Suggestions for future research are also provided.

Adolescents and their parents: a critical review of measures to assess their satisfaction with one another.

The importance of assessing the parent-adolescent relationship has been stressed in the literature. However, an integration of studies that have been conducted to assess satisfaction in the parent-adolescent relationship is warranted, including evaluation of measures to assess their satisfaction with one another. Therefore, the purpose of this paper is to provide a critical examination of the clinical utility and psychometric properties of such measures. Suggestions for future research are also provided.

Construct validity of the Babcock Story Recall Test.

The construct validity of the Babcock Story Recall Test (BSRT), a verbal memory measure, was examined by correlating its scores with scores on other neuropsychological tests in 71 substance abuse outpatients. Scores on the BSRT were strongly correlated with the Wechsler Memory Scale-Revised Logical Memory scores, although they were also correlated with some nonmemory indexes. The results provide some support for the construct validity of the BSRT as a measure of memory for structured verbal information.

Substance abuse treatment outcomes for cognitively impaired and intact outpatients.

The purpose of this research was to examine the effects of cognitive impairment on the efficacy of substance abuse treatment outcome. Alcohol, drug, medical, legal, psychological, employment, and family functioning related treatment outcomes were examined for 26 cognitively impaired and 68 cognitively intact abusing outpatients. Subjects were enrolled in an intensive, 3-week, outpatient program for the treatment of their substance abuse. Subjects were administered a battery of neuropsychological tests prior to treatment onset, and outcome data were obtained at 1, 3, 6, and 12 months posttreatment entry. No significant between-group differences were found on any of the outcome measures, and significant treatment gains were observed across all problem domains in both groups. Subjects' largest improvements were made in the first month of treatment for alcohol, drug, legal, family, and psychological problems. Improvements for employment and medical problems were not observed until 6 months posttreatment. Success across domains was maintained through 12 months follow-up, with the exception of psychological problems; 12-month data indicated a return to thelevel observed at 30 days posttreatment for psychological problems, a level that reflected significant improvement from baseline functioning. A greater proportion of treatment dropouts (i.e., no follow-up data obtained after 30 days) were cognitively impaired as compared to treatment completers. These results suggest that this method of intensive substance abuse outpatient treatment is effective for cognitively impaired patients, an important finding given that research evaluating the efficacy of interventions for such patients is limited. Additionally, neuropsychological evaluation may be important in reducing treatment dropouts, as the present findings indicated that greater cognitive impairment was related to an increased likelihood of treatment dropout.